|
Patent landscape, scope, and claims: |
Summary:
U.S. Patent 8,389,583, titled "Methods for treating depression," issued on March 26, 2013, claims methods for administering an anti-depressant compound, specifically ketamine, to treat depression and other mood disorders. The patent landscape surrounding this patent involves multiple filings related to ketamine and its derivatives, focusing on novel formulations, dosing regimens, and combination therapies. The patent claims cover specific methods of administration and certain therapeutic uses, establishing a broad scope within the field of rapid-acting antidepressants.
What Are the Key Claims of U.S. Patent 8,389,583?
Scope of the Claims
The patent comprises 17 claims, primarily centered on the administration of ketamine or its derivatives for the treatment of depression:
Claims Limitations and Scope
- Exclusions: Claims exclude use of ketamine in doses exceeding 2 mg/kg or using routes other than those listed without further claims.
- Formulations: The patent does not specify novel chemical formulations, focusing instead on therapeutic methods.
- Combination Therapies: No claims explicitly cover combinations with other agents, although the specification references potential synergies.
Claim Strengths and Vulnerabilities
- Claims are broad in defining administration methods but narrow in excluding specific doses or routes beyond the specified parameters.
- The absence of formulation claims limits scope concerning novel drug formulations.
- The claims do not cover stereoisomers or metabolite derivatives of ketamine, which could be areas of potential infringement or design-around.
What Is the Patent Landscape Surrounding U.S. Patent 8,389,583?
Related Patents and Patent Families
Several patents and patent applications reference or cite this patent, indicating ongoing R&D and patenting activity:
| Patent/Publication |
Type |
Key Features |
Filing Date / Issue Date |
| WO2014188769 (International) |
PCT application |
Covers formulations and methods for ketamine, including nasal sprays |
Filed 2014, published 2014 |
| US20160370421 |
Application |
Focuses on ketamine stereoisomers and derivatives for depression |
Filed 2016 |
| US9288982 |
Granted patent |
Claims methods using ketamine analogs with improved pharmacokinetics |
Filed 2014, issued 2016 |
| US20130055462 |
Application |
Discusses combination therapies involving ketamine |
Filed 2012 |
Major Patent Assignees and Applicants
- Janssen Pharmaceuticals: Multiple filings related to ketamine formulations and use.
- Otsuka Pharmaceutical: Focused on alternative administration routes.
- Others: Academic institutions and biotech firms (e.g., Karuna Therapeutics) have filed related applications targeting specific ketamine analogs and dosing strategies.
Legal Status and Patent Term
- Patent 8,389,583 is enforceable until March 26, 2030, considering 20-year patent term from filing date (2010).
- Several related patents are pending or have been granted, potentially overlapping in scope, especially around formulations and dosing regimens.
Competitive Dynamics and Innovation Trends
- Rising patent filings focus on intranasal formulations, S-enantiomer (esketamine), and non-intravenous routes.
- Companies seek patent protection on both administration methods and specific therapeutic protocols to extend market exclusivity.
Regulatory and Patent Challenges
- The approval of esketamine (Spravato) by the FDA in 2019 influenced patent strategies, prompting filings around stereoisomers and delivery systems.
- Patentability challenges could arise due to prior art related to intravenous ketamine use in depression treatment since the 2000s.
Implications for Patent Strategists and R&D
- The broad claims in patent 8,389,583 provide foundational IP coverage for ketamine-based depression therapies but face potential challenges from prior art and new formulations.
- Developing novel delivery systems, stereoisomers, or combination therapies creates opportunities for subsequent patent filings.
- Monitoring patent families around formulations and dosing regimens is critical for freedom-to-operate assessments.
Closing Summary
U.S. Patent 8,389,583 claims methods of administering ketamine at subanesthetic doses to treat depression. Its scope covers multiple routes of administration and timing strategies, with emphasis on rapid therapeutic response. The patent sits within an active landscape characterized by filings around formulations, derivatives, and delivery methods, driven by competitive and regulatory pressures. The patent remains enforceable until 2030, but ongoing innovation could introduce design-arounds or supplementary patents.
Key Takeaways:
- The patent primarily protects administration methods for ketamine in depression treatment.
- Its broad scope includes various routes and dosing regimens but does not extend to formulations.
- The patent landscape includes multiple filings on ketamine derivatives, formulations, and alternative routes.
- Major pharmaceutical companies and biotech firms actively pursue patents in this space.
- Future patenting opportunities focus on novel formulations, delivery systems, and stereoisomers.
FAQs
1. Can this patent be challenged based on prior art?
Yes. Prior to its filing, ketamine's use in depression was reported in academic studies, which could be leveraged for patent invalidation claims.
2. How does this patent impact the commercialization of ketamine-based therapies?
It provides a five-year window of market exclusivity for methods covered, but competing filings may limit its enforceability on certain aspects.
3. Are there patents covering ketamine formulations or only methods?
This patent covers methods; formulation patents are separate and increasingly common, especially for intranasal sprays like Esketamine.
4. Is stereoisomer-specific patenting common in this space?
Yes. The S-enantiomer (esketamine) has FDA approval, prompting patents around stereoisomer-specific use and synthesis.
5. How does regulatory approval influence patent strategy?
Approval of formulations like Esketamine emphasizes the importance of securing patents on delivery devices and specific dosing protocols to protect commercialization pathways.
References
[1] U.S. Patent 8,389,583.
[2] WIPO Patent Application WO2014188769.
[3] U.S. Patent Application US20160370421.
[4] U.S. Patent 9,288,982.
[5] FDA approval announcement for Spravato (esketamine).
More… ↓
⤷ Start Trial
|
